Crohn's Disease Clinical Trial
Official title:
Thalidomide in Inducing and Maintaining Remission of Crohn's Disease
Crohn's disease (CD) is a chronic gastrointestinal inflammatory disease characterized by
relapse and progression. The incidence and prevalence of IBD are increasing in different
regions around the world, indicating its emergence as a global disease. Though modern
medical therapies including immunomodulators and biologic agents have revolutionized
treatment of CD, the occurrence of steroids-dependence and resistance or intolerance to
medical therapy is quite common. The limitation of present therapeutic management and the
high expense of biologic agents leads to the treatment of CD become "refractoriness". The
occurrence rate of steroids-dependence and resistance or intolerance to thiopurine therapy
is quite high during the course of CD. Approximately 38% of cases required surgery within 10
years. Therefore, the management of such refractory CD remains a great therapeutic challenge
for clinicians.
Thalidomide is an oral agent that has immunomodulatory, antiangiogenic and TNF(tumor
necrosis factor)-a- suppressing effects. The potential role for thalidomide in the treatment
of refractory paediatric and adult CD has been investigated in more and more small
open-label studies and retrospective case series. Recently, a randomized controlled trial
showed thalidomide improved clinical remission at 8 weeks of treatment and longer-term
maintenance of remission in pediatric refractory CD. Gerich et al reported in a
retrospective study that thalidomide improved long-term outcomes among 37 refractory CD
adults followed up for a median of 58 months. However, the dose of thalidomide used in these
studies ranged from 50mg/d to 150mg/d, and the occurrence rate of side effects reported
variously but all quite high. The side effects related to the dose of thalidomide were the
major concerns of using it in CD. Moreover, the effect of thalidomide on endoscopic response
including mucosal healing which is a more objective and important outcome in CD was rarely
reported. Therefore the aim of this study is to investigate the efficacy on clinical and
endoscopic response and the adverse effects of using low-dose thalidomide in active adult CD
patients.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
| Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
| Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
| Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
| Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
| Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
| Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
| Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
| Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
| Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
| Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
| Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
| Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
| Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
| Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
| Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
| Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
| Completed |
NCT01951326 -
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
|
Phase 3 |